All verified mentions of this organization in source documents.
BioOrbit is working with relevant regulatory bodies to enable commercialisation of drugs manufactured in microgravity.
On February 9, 2026, the UK Space Agency awarded research contracts to BioOrbit, Space Forge, and OrbiSky to advance technology demonstration and commercialization of advanced materials manufacturing in low Earth orbit.
BioOrbit will use its UK Space Agency funding to design an end-to-end drug manufacturing mission in microgravity.
BioOrbit is a United Kingdom-based company developing a space-based pharmaceuticals factory.
BioOrbit Ltd received £250,000 for the PHARM study to design an end-to-end mission to manufacture drugs in microgravity.
BioOrbit is working with relevant regulators so medicines produced in space can be approved under the same regulatory framework as Earth-manufactured drugs.
BioOrbit positions PHARM’s objective of enabling space-manufactured drugs to meet the same regulatory standards as Earth-produced drugs as a world first.